Table 1.
Baseline IBD and cancer characteristics stratified by IBD activity at cancer diagnosis.
| Variable | Total | IBD inactive at cancer diagnosis | IBD active at cancer diagnosis |
|---|---|---|---|
| N (%) | 447 (100%) | 400 (89.5%) | 47 (10.5%) |
| IBD Subtype | |||
| Crohn’s disease | 197 (44.1%) | 175 (43.8%) | 22 (46.8%) |
| Ulcerative colitis | 238 (53.2%) | 214 (53.5%) | 24 (51.0%) |
| Indeterminate colitis | 12 (2.7%) | 11 (2.8%) | 1 (2.1%) |
| Sex | |||
| Female | 346 (77.4%) | 315 (78.8%) | 31 (66.0%) |
| Male | 101 (22.6%) | 85 (21.3%) | 16 (34.0%) |
| Race | |||
| White | 388 (86.8%) | 353 (88.3%) | 35 (74.5%) |
| Black | 18 (4.0%) | 15 (3.8%) | 3 (6.4%) |
| Hispanic | 12 (2.7%) | 9 (2.3%) | 3 (6.4%) |
| Asian | 11 (2.5%) | 9 (2.3%) | 2 (4.3%) |
| Unknown | 18 (4.0%) | 14 (3.5%) | 4 (8.6%) |
| Median age at IBD diagnosis (range) | 41 (4–90) | 40 (4–90) | 47 (15–68) |
| Smoking history at cancer diagnosis | |||
| Never | 230 (51.5%) | 207 (51.8%) | 23 (48.9%) |
| Former | 200 (44.7%) | 178 (44.5%) | 22 (46.8%) |
| Current | 17 (3.8%) | 15 (3.8%) | 2 (4.3%) |
| Primary sclerosing cholangitis | 8 (1.8) | 7 (1.8%) | 1 (2.1%) |
| IBD treatment before cancer | |||
| 5-ASA | 227 (50.8%) | 190 (47.5%) | 37 (78.7%) |
| Steroids | 115 (25.7%) | 91 (22.8%) | 24 (51.1%) |
| Immunomodulators | 69 (15.4%) | 55 (13.8%) | 14 (29.8%) |
| Biologics | 26 (5.8%) | 18 (4.5%) | 8 (17.0%) |
| Infliximab | 14 (53.8%) | 10 (55.6%) | 4 (50%) |
| Adalimumab | 9 (34.6%) | 6 (33.3%) | 3 (37.5%) |
| Certolizumab pegol | 3 (11.5%) | 2 (11.1%) | 1 (12.5%) |
| Golimumab | 0 | 0 | 0 |
| Vedolizumab | 0 | 0 | 0 |
| Ustekinumab | 0 | 0 | 0 |
| Previous surgery for IBD | 123 (27.5%) | 107 (26.8%) | 16 (34.0%) |
| Type of Cancer | |||
| Breast | 346 (77.4%) | 315 (78.8%) | 31 (68.1%) |
| Prostate | 101 (22.6%) | 85 (21.3%) | 16 (31.9%) |
| Median age at cancer diagnosis (range) | 58 (23–90) | 57 (28–90) | 62 (38–80) |
| Cancer stage at diagnosis | |||
| I | 160 (25.8%) | 138 (34.5%) | 22 (46.8%) |
| II | 65 (14.5%) | 60 (15.0%) | 5 (10.6%) |
| III | 24 (5.4%) | 21 (5.3%) | 3 (6.4%) |
| IV | 7 (1.6%) | 6 (1.5%) | 1 (2.1%) |
| Unknown | 191 (42.7%) | 175 (43.8%) | 16 (34.0%) |
| Cancer treatment | |||
| Surgery | 384 (85.9%) | 344 (86.0%) | 40 (85.1%) |
| Radiotherapy | 255 (57.0%) | 225 (56.3%) | 30 (63.8%) |
| Immune therapies | 12 (2.7%) | 11 (2.8%) | 1 (2.1%) |
| Cytotoxic chemotherapy only | 34 (7.6%) | 34 (8.5%) | 0 |
| Hormone therapy only | 187 (41.8%) | 164 (41.0%) | 23 (48.9%) |
| Median duration of hormone therapy (range) | 60 (1–149) | 60 (1–149) | 60 (1–120) |
| Cytotoxic chemotherapy and hormone therapy | 73 (16.3%) | 65 (16.3%) | 8 (17.0%) |
| Neither cytotoxic nor hormone therapy | 113 (25.3%) | 100 (25.0%) | 13 (27.7%) |
| Unknown | 40 (8.9%) | 37 (9.3%) | 3 (6.4%) |